Belvedere Trading
IOVA icon

Belvedere Trading’s Iovance Biotherapeutics IOVA Stock Holding History

Belvedere Trading’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,000
Closed -$14.8K – 800
2024
Q1 		$14.8K Buy
+1,000
New +$11.6K ﹤0.01% 591

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Belvedere Trading's IOVA Position: Q1 2024 in Review

Belvedere Trading sold out of Iovance Biotherapeutics (IOVA) in Q1 2024, closing a stake of 4,323 shares — an estimated $50.3K sold.

Belvedere Trading first reported a position in IOVA in Q1 2022 and held it in 3 quarters. The position peaked at $275K in Q1 2022. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

  • Belvedere Trading reported no remaining Iovance Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Belvedere Trading sold 4,323 Iovance Biotherapeutics shares in Q1 2024, an estimated $50.3K.
  • Belvedere Trading first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 3 quarters.
  • Belvedere Trading's Iovance Biotherapeutics position peaked at $275K in Q1 2022.
  • 273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.